Videos and Podcasts

7th May 20

Acquisdata Podcast with Gary Phillips on COVID-19 Impact and Response.

Gary Phillips, CEO of Australian biopharma company, Pharmaxis Ltd, discusses ensuring continuity of supply of its products throughout the crisis, the timeframe for trials of its unique anti-fibrotic treatment for a rare bone cancer, broader impacts for biopharma research and trials, the opportunity for the global industry and the potential for PXS respiratory products in the clinical aftermath of COVID -19.

Recorded 29 April 2020.

Listen to the podcast here.

4th May 20

Pharmaxic CEO Gary Phillips Presentation to NWR Virtual Health Conference

Pharmaxis Ltd (ASX: PXS) chief executive officer Mr Gary Phillips presented at the NWR Virtual Health Conference on Friday 1 May 2020. 

Investors may view a recording of the presentation at the NWR website:   https://us02web.zoom.us/webinar/register/WN_pdWZYlHJRFmjH01LYGc0NQ

30th Apr 20

Pharmaxis to progress myelofibrosis drug to Phase II following positive results

Gary Phillips tells Proactive's Andrew Scott they're progressing to a phase II study of its oral anti-fibrotic pan-Lysyl Oxidase (LOX) inhibitor PXS-5505 for treatment of the rare bone cancer, myelofibrosis (MF). The move comes on the back of positive results from its phase 1b trial and long-term toxicity studies.

Watch interview